{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T03:23:57Z","timestamp":1649042637381},"reference-count":93,"publisher":"Oxford University Press (OUP)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11,1]]},"DOI":"10.2146\/ajhp090147","type":"journal-article","created":{"date-parts":[[2010,10,21]],"date-time":"2010-10-21T16:33:56Z","timestamp":1287678836000},"page":"1813-1824","source":"Crossref","is-referenced-by-count":1,"title":["Standard of care and novel treatments for chronic lymphocytic leukemia"],"prefix":"10.1093","volume":"67","author":[{"given":"Amy Hatfield","family":"Seung","sequence":"first","affiliation":[{"name":"Oncology Pharmacy Residency, Johns Hopkins Hospital, 600 North Wolfe Street\/Carnegie 180, Baltimore, MD 21287a"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041104314032100_b1-0671813","volume-title":"Cancer facts and figures 2008","year":"2008"},{"key":"key\n\t\t\t\t2019041104314032100_b2-0671813","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2007.06791.x","article-title":"Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients","volume":"139","author":"Shanafelt","year":"2007","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t2019041104314032100_b3-0671813","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-145-6-200609190-00007","article-title":"Initial management of newly diagnosed, early-stage chronic lymphocytic leukemia","volume":"145","author":"Shanafelt","year":"2006","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041104314032100_b4-0671813","unstructured":"United States National Institutes of Health. www.clinicaltrials.gov (accessed 2010 Mar 1)."},{"key":"key\n\t\t\t\t2019041104314032100_b5-0671813","article-title":"Chronic lymphocytic leukemia","volume-title":"Cancer: principles and practice of oncology","author":"Wierda","year":"2005"},{"key":"key\n\t\t\t\t2019041104314032100_b6-0671813","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ajh.2830290307","article-title":"Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group","volume":"29","author":"Cheson","year":"1988","journal-title":"Am J Hematol"},{"key":"key\n\t\t\t\t2019041104314032100_b7-0671813","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy","volume":"92","author":"Keating","year":"1998","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b8-0671813","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b9-0671813","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019041104314032100_b10-0671813","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041104314032100_b11-0671813","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b12-0671813","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/01.cco.0000181403.75460.c7","article-title":"New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia","volume":"17","author":"Gentile","year":"2005","journal-title":"Curr Opin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b13-0671813","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041104314032100_b14-0671813","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b15-0671813","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2002-06-1801","article-title":"The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression","volume":"101","author":"Ghia","year":"2003","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b16-0671813","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood.V98.9.2633","article-title":"Clinical significance of CD38 expression in chronic lymphocytic leukemia","volume":"98","author":"Del Poeta","year":"2001","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b17-0671813","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b18-0671813","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood-2001-11-0066","article-title":"Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia","volume":"100","author":"Lin","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b19-0671813","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"Krober","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b20-0671813","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041104314032100_b21-0671813","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","article-title":"ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile","volume":"101","author":"Wiestner","year":"2003","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b22-0671813","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.leu.2402531","article-title":"Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia","volume":"16","author":"Robak","year":"2002","journal-title":"Leukemia"},{"issue":"2 suppl 5","key":"key\n\t\t\t\t2019041104314032100_b23-0671813","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1053\/j.seminoncol.2006.01.026","article-title":"Beyond detectable minimal residual disease in chronic lymphocytic leukemia","volume":"33","author":"Hillmen","year":"2006","journal-title":"Semi Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b24-0671813","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival","volume":"23","author":"Moreton","year":"2005","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b25-0671813","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ctrv.2006.05.002","article-title":"Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis","volume":"32","author":"Steurer","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"key\n\t\t\t\t2019041104314032100_b26-0671813","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/asheducation-2006.1.285","article-title":"Current and investigational therapies for patients with CLL","volume":"2006","author":"Wierda","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key\n\t\t\t\t2019041104314032100_b27-0671813","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041104314032100_b28-0671813","unstructured":"Bayer Healthcare Pharmaceuticals and Genzyme Corporation. Fludara (fludarabine phosphate) prescribing information. www.fludarabine.com\/pi.html (accessed 2008 Jul 16)."},{"key":"key\n\t\t\t\t2019041104314032100_b29-0671813","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/10428199309054731","article-title":"Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine","volume":"11","author":"Di Raimondo","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t2019041104314032100_b30-0671813","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1600-0609.1997.tb00933.x","article-title":"Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine)","volume":"58","author":"Robak","year":"1997","journal-title":"Eur J Haematol"},{"key":"key\n\t\t\t\t2019041104314032100_b31-0671813","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b32-0671813","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b33-0671813","doi-asserted-by":"crossref","first-page":"212a","DOI":"10.1182\/blood.V106.11.716.716","article-title":"Early results from LRF CLL4: a UK multicenter randomized trial","volume":"106","author":"Catovsky","year":"2005","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b34-0671813","doi-asserted-by":"crossref","first-page":"194a","DOI":"10.1182\/blood.V110.11.630.630","article-title":"Cladribine (CdA) gives longer response duration than fludarabine (F) and high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia (CLL). First results from the international randomized phase III trial","volume":"110","author":"Karlsson","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b35-0671813","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/cncr.24003","article-title":"Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1\/TP53 deletion: report from the Polish Adult Leukemia Group","volume":"115","author":"Robak","year":"2009","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019041104314032100_b36-0671813","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1989.7.4.433","article-title":"Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia Group B","volume":"7","author":"Dillman","year":"1989","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b37-0671813","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/1042819031000151897","article-title":"Pentostatin, chlorambucil, and prednisone therapy for B-chronic lymphocytic leukemia: a phase I\/II study by the ECOG Study E1488","volume":"45","author":"Oken","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t2019041104314032100_b38-0671813","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","article-title":"Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia","volume":"109","author":"Kay","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b39-0671813","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b40-0671813","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b41-0671813","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long term results of the fludarabine, cyclophosphamide & rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b42-0671813","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b43-0671813","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b44-0671813","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1634\/theoncologist.2007-0218","article-title":"FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia","volume":"13","author":"Demko","year":"2008","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t2019041104314032100_b45-0671813","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23824","article-title":"Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab","volume":"113","author":"Zent","year":"2008","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019041104314032100_b46-0671813","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/cncr.23271","article-title":"Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network","volume":"112","author":"Hainsworth","year":"2008","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019041104314032100_b47-0671813","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2141.2008.07394.x","article-title":"Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)","volume":"144","author":"Schweighofer","year":"2009","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t2019041104314032100_b48-0671813","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2165\/00003495-200161050-00009","article-title":"Bendamustine","volume":"61","author":"Balfour","year":"2001","journal-title":"Drugs"},{"key":"key\n\t\t\t\t2019041104314032100_b49-0671813","unstructured":"Cephalon. Treanda (bendamustine hydrochloride) prescribing information. www.treanda.com (accessed 2008 Jul 8)."},{"key":"key\n\t\t\t\t2019041104314032100_b50-0671813","first-page":"1357","article-title":"Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I\/II study of the German CLL Study Group","volume":"90","author":"Bergmann","year":"2005","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t2019041104314032100_b51-0671813","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with CLL","volume":"27","author":"Knauf","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b52-0671813","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival","volume":"23","author":"Moreton","year":"2005","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b53-0671813","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cncr.23144","article-title":"Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia","volume":"112","author":"Del Poeta","year":"2008","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019041104314032100_b54-0671813","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","article-title":"Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission\u2014 experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)","volume":"18","author":"Wendtner","year":"2004","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t2019041104314032100_b55-0671813","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood-2005-02-0819","article-title":"How I treat refractory CLL","volume":"107","author":"Montserrat","year":"2006","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b56-0671813","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/cncr.24329","article-title":"Treatment of fludarabine-refractory chronic lymphocytic leukemia","volume":"115","author":"Tsimberidou","year":"2009","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019041104314032100_b57-0671813","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2141.2008.07451.x","article-title":"Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia","volume":"144","author":"Karlsson","year":"2009","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t2019041104314032100_b58-0671813","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/10428190902763541","article-title":"Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia","volume":"50","author":"Ferrajoli","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t2019041104314032100_b59-0671813","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b60-0671813","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1046\/j.1365-2141.2002.03959.x","article-title":"Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia","volume":"119","author":"Bosch","year":"2002","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t2019041104314032100_b61-0671813","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/1042819031000123546","article-title":"Bendamustine plus mitoxantrone\u2014a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I\/II study","volume":"45","author":"Koppler","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t2019041104314032100_b62-0671813","doi-asserted-by":"crossref","first-page":"213a","DOI":"10.1182\/blood.V106.11.719.719","article-title":"Salvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL","volume":"106","author":"Wierda","year":"2005","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b63-0671813","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b64-0671813","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.2001.19.5.1414","article-title":"Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b65-0671813","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b66-0671813","doi-asserted-by":"crossref","first-page":"913a","DOI":"10.1182\/blood.V110.11.3106.3106","article-title":"Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG)","volume":"110","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b67-0671813","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b68-0671813","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1200\/JCO.2005.01.9950","article-title":"Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial","volume":"23","author":"Elter","year":"2005","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b69-0671813","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2002-07-1952","article-title":"Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies","volume":"101","author":"Faderl","year":"2003","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b70-0671813","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b71-0671813","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indications for allogenic transplantation in CLL: the EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t2019041104314032100_b72-0671813","first-page":"397a","article-title":"Autologous stem-cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL): results in 107 patients","volume":"94","author":"Montserrat","year":"1999","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b73-0671813","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b74-0671813","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/bmt.2009.61","article-title":"Reduced intensity versus full myeloablative stem cell transplant for advanced CLL","volume":"44","author":"Peres","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t2019041104314032100_b75-0671813","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood.V92.10.3804","article-title":"Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53","volume":"92","author":"Byrd","year":"1998","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b76-0671813","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b77-0671813","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1158\/1078-0432.CCR-04-2276","article-title":"Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805","volume":"11","author":"Byrd","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041104314032100_b78-0671813","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.leukres.2005.03.010","article-title":"Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity","volume":"29","author":"Flinn","year":"2005","journal-title":"Leuk Res"},{"key":"key\n\t\t\t\t2019041104314032100_b79-0671813","first-page":"855","article-title":"Oblimersen for the treatment of patients with chronic lymphocytic leukemia","volume":"3","author":"Cheson","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"key\n\t\t\t\t2019041104314032100_b80-0671813","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/108729002760220798","article-title":"Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment","volume":"12","author":"Klasa","year":"2002","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"key\n\t\t\t\t2019041104314032100_b81-0671813","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","article-title":"Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"25","author":"O\u2019Brien","year":"2007","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b82-0671813","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1200\/JCO.1994.12.10.2146","article-title":"Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia","volume":"12","author":"Reinisch","year":"1994","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b83-0671813","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1158\/1078-0432.CCR-06-1463","article-title":"Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"13","author":"Byrd","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041104314032100_b84-0671813","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2009-08-237727","article-title":"Phase 1\/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"115","author":"Byrd","year":"2010","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b85-0671813","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2001.19.16.3611","article-title":"Impact of therapy with chlorambucil, fludarabine, or fludarabine and chlorambucil on infections in patients with CLL: Intergroup Study Cancer and Leukemia Group B 9011","volume":"19","author":"Morrison","year":"2006","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041104314032100_b86-0671813","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2009.12.004","article-title":"Infectious complications of chronic lymphocytic leukemia: pathogenesis, spectrum of infection, preventive approaches","volume":"23","author":"Morrison","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"key\n\t\t\t\t2019041104314032100_b87-0671813","unstructured":"Bayer HealthCare Pharmaceuticals and Genzyme Corporation. Campath (alemtuzumab) prescribing information. http:\/\/berlex.bayerhealthcare.com\/html\/products\/pi\/Campath_PI.pdf (accessed 2009 Feb 13)."},{"key":"key\n\t\t\t\t2019041104314032100_b88-0671813","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1056\/NEJM198810063191403","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial","volume":"319","author":"Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia","year":"1988","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041104314032100_b89-0671813","first-page":"121","article-title":"Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study","volume":"81","author":"Molica","year":"1996","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t2019041104314032100_b90-0671813","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/1042819031000063408","article-title":"Vaccination against infections in chronic lymphocytic leukemia","volume":"44","author":"Sinisalo","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t2019041104314032100_b91-0671813","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a full human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1\u20132 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041104314032100_b92-0671813","unstructured":"GlaxoSmithKline. Arzerra (ofatumumab package insert). us.gsk.com\/products\/assets\/us_arzerra.pdf (accessed 2010 Sep 20)."},{"key":"key\n\t\t\t\t2019041104314032100_b93-0671813","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab a single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/67\/21\/1813\/28345287\/ajhp1813.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T05:00:44Z","timestamp":1592024444000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/67\/21\/1813\/5129968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,1]]},"references-count":93,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2010,11,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp090147","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,11,1]]},"published":{"date-parts":[[2010,11,1]]}}}